Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Pleomorphic xanthoastrocytoma (PXA) is a rare pediatric low-grade glioma (pLGG), of which 60%-80% exhibit the BRAF V600E mutation, that enhances the aggressiveness and progression to an eventual pediatric high-grade glioma (pHGG). Despite the aggressiveness of this mutational status, the mechanisms underlying the progression of BRAF V600E tumors remain poorly understood, primarily due to limited insights into their growth dynamics. In this issue, Rajappa and colleagues leverage a novel immunocompetent RCAS-BRAF V600E murine glioma model to profile the immunological dynamics taking place in BRAF V600E pLGG.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11347045 | PMC |
| http://dx.doi.org/10.1016/j.omton.2024.200853 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multimodal ultrasonographic and clinicopathological model for predicting high-volume lymph node metastasis in cN0 papillary thyroid carcinoma.
Front Endocrinol (Lausanne)
September 2025
Department of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Background: Given the challenge in preoperative diagnosis of high-volume lymph node metastasis (HVLNM) in clinical practice, we constructed and externally validated a comprehensive predictive model that integrated conventional ultrasound characteristics, contrast-enhanced ultrasound (CEUS) parameters, BRAFmutation, and clinicopathological data for HVLNM in clinically lymph node-negative (cN0) papillary thyroid carcinoma (PTC).
Methods: Totally, 126 clinically lymph node-negative (cN0) PTC patients who underwent subtotal or total thyroidectomy and accompanied with prophylactic cervical lymph node dissection between December 2022 and December 2024 were enrolled in this retrospective study, and an additional 47 cN0 PTC patients included for the external validation cohort. Univariate and multivariate analysis were performed to identify the independent risk factors for HVLNM, and a binary logistic regression equation and relevant nomogram was constructed to predict the risk about HVLNM.
Pulmonary Langerhans cell histiocytosis (PLCH) is a rare diffuse lung disease that is strongly associated with cigarette smoking, with the BRAF V600E mutation identified in approximately half of all cases. In Japan, combination therapy with BRAF and MEK inhibitors has recently been approved as an alternative treatment option. We report the case of a 30-year-old woman diagnosed with BRAF V600E-mutant PLCH who was treated with dabrafenib in combination with trametinib.
View Article and Find Full Text PDFTargeting melanoma resistance: Novel oxindole and non-oxindole-based benzimidazole derivatives as potent dual inhibitors of BRAF and ABL2 kinases.
Eur J Med Chem
August 2025
Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, 61519, Minia, Egypt.
Melanoma is one of the deadliest forms of cancer. The disease is incurable for many due to its aggressive, metastatic characteristics and its elevated resistance. Herein, we design and synthesize two series of target compounds oxindole-based (7a-h) and non-oxindole-based (8a-h) benzimidazole.
View Article and Find Full Text PDFThe intrinsic ability of cancer cells to evade death underpins tumorigenesis, progression, metastasis and the survival of drug-tolerant persister (DTP) cells. Herein, we discovered that when activated, the small GTPase ARF6 plays a central role in tumor survival by facilitating expression of the BRAF oncoprotein. Tumor-specific deletion caused a significant reduction in BRAF protein and MAPK signaling and prevented rapid tumor progression.
View Article and Find Full Text PDFCytologic atypia is predictive of increased risk of malignancy and BRAF mutations in thyroid follicular neoplasms (Bethesda category IV).
J Am Soc Cytopathol
July 2025
Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Introduction: Molecular testing on thyroid fine needle aspirations with indeterminate cytology is integral to patient management. The aim of this study was to investigate the risk of malignancy in nodules diagnosed as Bethesda category IV, follicular neoplasm (FN), with and without cytologic atypia.
Methods: A total of 186 thyroid fine needle aspirations classified as Bethesda category IV (FN) were identified, and were categorized as FN with cytologic atypia or without cytologic atypia.